When we discuss risk, it’s often focused on the negative threats where there is a need to mitigate or avoid threats to the project that could impact timelines, deliverables or quality. One can look at risk as simply uncertainty. From that view, risk can also represent positive opportunities to improve the speed of delivery for certain aspects of the study, or perhaps even cost savings or efficiencies.
Authors
- Alexander Watt, Global Head, IQVIA Laboratories Biotech
- Alan Wookey, B.Sc., Scientific Advisor, Oncology, IQVIA Laboratories
Complete the form below to access this insight brief
Related Insights
Managing Informed Consent Samples from Clinical Trials
A set of best practices for the definition, tracking and management of allowable use attributes associated with samples collected in protocol based clinical trials
Labmatrix®
Tracking clinical trial samples and consents to support total sample lifecycle management
Consent Tracking for Clinical Trial Samples
Optimizing the management of consents throughout the entire lifecycle
Tracking Clinical Trial Samples
Optimizing the management of samples throughout the entire lifecycle
Blockchain in Clinical Research Sample Management
Distributed Ledger Technology (DLT) in clinical trials
Managing Sample Data from Vendors
Best Practices for Clinical Trials
Using Labmatrix® at a Big Biopharma Company to Reduce Clinical Trial Delays, Costs and Regulatory Risks
Managing Sample Data from Vendors
Best practices for clinical trials
eConsent and BioBanking
How to reduce costs while improving efficiencies
Key Central Laboratory Capabilities to Enable Successful Immuno-Oncology Clinical Development
Trends and recommendations in laboratory selection
